Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Abstract

INTRODUCTION MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase. Though only in early clinical testing, this agent holds great promise in diseases thought to be driven by c-MET activation, as evidenced by the Phase II results in NSCLC where a benefit in overall survival was observed in patients… (More)
DOI: 10.1517/14712598.2011.626762

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.